Inhibitor Therapeutics Inc INTI:OTCQB

RT Quote | Exchange | USD
Last | 03/05/21 EST
0.09quote price arrow down-0.0002 (-0.2217%)
Volume
474
52 week range
0.02 - 0.16

...

Loading . . .

KEY STATS

  • Open0.0997
  • Day High0.0997
  • Day Low0.09
  • Prev Close0.0902
  • 52 Week High0.16
  • 52 Week High Date02/24/21
  • 52 Week Low0.02
  • 52 Week Low Date01/20/21
  • Market Cap33.63M
  • Shares Out373.64M
  • 10 Day Average Volume0.00M
  • Dividend-
  • Dividend Yield-
  • Beta-0.29
  • 1 Year % Change47.3

RATIOS/PROFITABILITY

  • EPS (TTM)-0.00
  • P/E (TTM)-23.81
  • Fwd P/E (NTM)-
  • EBITDA (MRQ)-1.641M
  • ROE (MRQ)-8,850.31%
  • Revenue (MRQ)0.00
  • Gross Margin (MRQ)-
  • Net Margin (MRQ)-
  • Debt To Equity (MRQ)-1.23%

EVENTS

  • Earnings Date-
  • Ex Div Date-
  • Div Amount-
  • Split Date-
  • Split Factor-

Latest Inhibitor Therapeutics Inc News

There is no recent news for this security.

Latest INTI News From Our Partners

There is no recent news for this security.

QUOTE FINDER

Profile

MORE
Inhibitor Therapeutics, Inc., formerly HedgePath Pharmaceuticals, Inc., is a pharmaceutical development company. The Company is focused on developing therapeutics to inhibit the progression of cancerous and non-cancerous proliferation disorders. It is focused on developing its lead product, SUBA-Itraconazole, an oral formulation of anti-fungal drug, Itraconazole, for prostate and lung cancer. SUBA-Itraconazole is designed to enable absorption and reduced variability compared...
William Watson CPA
Chairman
Nicholas Virca
President
Garrison Hasara CPA
Chief Financial Officer
Address
4830 W. Kennedy Blvd., Suite 600
Tampa, FL
33609
United States